Bezuclastinib

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

19 evidence topics · 10 sources

Trigger avoidance and patient education1 evidence topic · 1 source
H1 and h2 antihistamines2 evidence topics · 2 sources
Proton pump inhibitors1 evidence topic · 1 source
Leukotriene receptor antagonists1 evidence topic · 1 source
Mast cell stabilizers1 evidence topic · 1 source
Epinephrine1 evidence topic · 1 source
Corticosteroids1 evidence topic · 1 source
Anti-IgE monoclonal antibodies1 evidence topic · 1 source
KIT tyrosine kinase inhibitors2 evidence topics · 5 sources
Cytoreductive therapies1 evidence topic · 1 source
Bone-directed therapies1 evidence topic · 1 source
Venom immunotherapy1 evidence topic · 1 source
Vascular laser therapy1 evidence topic · 1 source
Clinical trials2 evidence topics · 2 sources
Limitations of current therapies2 evidence topics · 5 sources